13.6 C
London
Wednesday, October 15, 2025
HomeBusinessMission Therapeutics: Raises $15M in Funding

Mission Therapeutics: Raises $15M in Funding

Related stories

BoE to Prioritize AI, DLT, and Quantum Computing in Tech Strategy

Exploring the Future of Financial Technology Governance and InnovationHighlights:...

BoE Prioritizes AI, DLT, and Quantum Computing in Tech Strategy

Exploring the Future of Financial Technology at the Bank...

Allianz UK Appoints First Head of AI: A New Era in Artificial Intelligence Leadership

Exploring the Implications of Allianz UK's Major AI Appointment...

SBS Transforms Its Image: Leading the Charge in Fintech Innovation

Discover how SBS is reshaping its future by embracing...

Lunar Achieves Milestone as First Scandinavian Provider to Obtain MiCA Crypto License

Revolutionizing the Crypto Landscape in Scandinavia: Lunar's Groundbreaking License...

Mission Therapeutics: Raises $15M in Funding

  • Mission Therapeutics focused on selectively inhibiting deubiquitylating enzymes (DUBs), raised $15m (£12m) in equity funding
  • Then the round was led by existing investor Pfizer Ventures, the venture capital arm of Pfizer Inc. (NYSE: PFE)
  • All other existing investors (Sofinnova Partners, Roche Venture Fund, SR One, IP Group and Schroders Adveq) joined the round on a pro rata basis
  • Mission and Pfizer Inc. have also expanded their relationship by entering into an evaluation and option agreement for DUB target validation
  • The company intends to use the funds for the development of its DUB platform, as well as growth of its pipeline of DUB inhibitor programmes
  • To date, Mission has received £73m / $101m in funding. and is based at the Babraham Research Campus, Cambridge, UK

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Latest stories

spot_img